VBI VACCINES INC. (TSE:VBV) Files An 8-K Other EventsItem 8.01 Other Events.
On January 17, 2018, VBI Vaccines Inc. issued a press release announcing that the first patient has been dosed in a Phase 1/2a clinical study of VBI-1901 for the treatment of recurrent glioblastoma multiforme (GBM). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Press Release dated January 17, 2018 |
VBI Vaccines Inc/BC ExhibitEX-99.1 2 ex99-1.htm VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901 ● Two-part Phase 1/2a study of VBI-1901 to enroll patients with recurrent GBM ● Part A: Dose escalation to enroll up to 18 patients ● Part B: Subsequent extension of optimal dose to enroll up to 10 additional patients CAMBRIDGE,…To view the full exhibit click here
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).